Fibrolamellar carcinoma is a rare liver cancer with limited systemic treatment options. This study identifies CXCR4 chemokine signaling as a key driver of immune exclusion in fibrolamellar carcinoma. Therapeutically targeting CXCR4 potentiates PD-1 blockade, together representing a new combination immunotherapy approach.
Gastroenterology (AGA) published a clinical update in Research Highlights on 17 Feb 2026.
The item focuses on Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma.
Review the original article for the full source wording and details.